• By Kevin E. Noonan —

    Federal Circuit SealLast week, the Federal Circuit affirmed a jury verdict against Baxalta Inc., Baxalta US Inc., and Nektar Therapeutics for infringing Bayer Healthcare's patent to human blood clotting factor conjugates in Bayer Healthcare LLC v. Baxalta Inc.

    Bayer Healthcare sued Defendants on U.S. Patent No. 9,364,520, alleging willful infringement by Baxalta's product, Adynovate®.  This product is a recombinant human Factor VIII (the blood clotting factor responsible for causing Hemophilia A) having the protein structural domains A1-A2-B-A3-C1-C2, wherein the B portion was specifically modified by addition of polyethylene glycol (PEG).  PEGylation is important because Factor VIII has an 11-hour half-life which requires frequent injections and leads to reduced patient compliance.  The prior art had disclosed "random" modification of Factor VIII with PEG, which had "several drawbacks" due to the multiplicity of PEGylations sites ("158 lysines, the two N-termini, and multiple histidines, serines, threonines, and tyrosines") in the Factor VIII protein, which led to heterogeneity in the species produced, including ones having deleterious effects on Factor VIII activity and ones having a multiplicity of PEG residues conjugated to the protein.

    The '520 patent specification disclosed site-specific PEGylation at a site not at an N-terminal amine; claim 1 is representative:

    1.  An isolated polypeptide conjugate comprising a functional factor VIII polypeptide and one or more biocompatible polymers, wherein the functional factor VIII polypeptide comprises the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof and has a B-domain, and further wherein the biocompatible polymer comprises polyalkylene oxide and is covalently attached to the functional factor VIII polypeptide at the B-domain.

    (wherein the italicized portions of the claim identify claim language disputed in the litigation).

    At trial, the District Court construed the term "isolated polypeptide conjugate" to mean "a polypeptide conjugate where conjugation was not random."  Specifically, the District Court held that during prosecution of the '520 patent, Bayer had disclaimed embodiments having random PEGylation.  Further, the District Court construed the term "at the B-domain" to mean "attachment at the B-domain such that the resulting conjugate retains functional factor VIII activity," rejecting Baxalta's proposed construction that the phrase should be construed to mean "at a site that is not any amine or carboxy site in factor VIII and is in the B-domain."  The District Court granted Defendants' pre-trial motion as a matter of law that there was no willful infringement, and a jury found that Defendants infringed claims 1-3 and 8 of the '520 patent.  The jury found against Defendants' counterclaim of non-enablement, and awarded Bayer $155,190,264 in reasonable royalty damages, based on a 17.78% royalty rate for $872,836,128 in Defendants' profits.  The District Court also denied Defendants' JMOL motions on the issues of infringement, enablement, and damages.  Bayer filed a motion under Federal Rule of Civil Procedure 59(a) for pre-verdict supplemental damages, which the District Court granted and awarded Bayer another $18,324,562.  The District Court also denied Bayer's motion for JMOL on willful infringement.  Both parties appealed.

    The Federal Circuit affirmed, in an opinion by Judge Stoll, joined by Judges Newman and Linn.  The opinion first opined on the District Court's claim construction, which (because the District Court had not relied upon extrinsic evidence) was performed de novo, with regard to the interpretation of the terms "at the B-domain" and "random" PEGylation of the B portion of Factor VIII.  The opinion rejected Defendants' argument that the term "at the B-domain" should have been interpreted to exclude amine/lysine PEG conjugation.  The opinion sets forth its claim construction analysis by way of the factors enunciated in Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc):  plain meaning of the claim terms, the specification, and the prosecution history.  The Federal Circuit found the plain meaning of the term "'[a]n isolated polypeptide conjugate' in which PEG 'is covalently attached to the functional factor VIII polypeptide at the B-domain'" does not require any particular amino acid residue to be PEGylated, saying that the claim "broadly requires PEGylation at the B-domain as a region."  The panel identified statements in the specification that supported this construction, and while acknowledging that PEGylation at cysteine residues was expressly disclosed, held that this disclosure did not limit the scope of site-specific PEGylation to just cysteine residues.  The Federal Circuit also disagreed with Defendants that the specification disparaged amine/lysine PEG conjugation, expressly based on Indivior Inc. v. Dr. Reddy's Laboratories, S.A., 930 F.3d 1325 (Fed. Cir. 2019); Gaus v. Conair Corp., 363 F.3d 1284 (Fed. Cir. 2004); and SciMed Life Systems, Inc. v. Advanced Cardiovascular Systems, Inc., 242 F.3d 1337 (Fed. Cir. 2001) (although the opinion states that it was a close question).  Rather than disparaging or disclaiming any particular type of conjugation with PEG, the panel held that the '520 patent specification disparaged random PEGylation (which is not the same thing).  Finally, the opinion held that nothing in the prosecution history was to the contrary, specifically in that it did not contain "a clear and unmistakable surrender of claims directed to non-random amine/lysine PEGylation."  While art cited by the USPTO included amine/lysine conjugation sites, taken as a whole and as understood by a person of ordinary skill in the art, the Federal Circuit held the rejection and cited art was directed to random PEGylation.  (And Defendants' citation of statements made in the prosecution of related European Patent Application No. 11153287.4 were unavailing, both on the merits and, in agreement with the District Court, "varying legal and procedural requirements for obtaining patent protection in foreign countries might render consideration of certain types of representations inappropriate for consideration in a claim construction analysis of a United States counterpart.")

    With regard to the term "random," the Federal Circuit rejected Defendants' argument that the District Court had erred by not expressly defining the term, thus improperly leaving construction of this term to the jury.  The panel held that the District Court had "resolved the parties' differences" with regard to this term by addressing (and rejecting) Defendants' arguments that "(1) that 'random' conjugation means any conjugation at amines or carboxy sites; and (2) that 'random' conjugation means all heterogenous conjugation."  The Federal Circuit understood the District Court's construction did not exclude any degree of heterogeneity from PEG conjugation but rather that Bayer had disparaged embodiments with "a high degree of heterogeneity" (which was the problem with prior art embodiments of PEGylated Factor VIII preparations that distinguished Bayer's invention).  Reciting the District Court's construction, the opinion states that the District Court found (correctly) that "non-random conjugation neither required that each FVIII protein in a product such as Adynovate® be PEGylated in the same places (homogeneity among conjugates in the product) nor required that every PEG on each FVIII protein be in the B-domain (homogeneity within each conjugate)."  Accordingly, the Federal Circuit held that limiting the term "random" with reference to construction of the term "isolated polypeptide conjugate" to mean "a polypeptide conjugate where conjugation was not random" sufficiently defined the meaning of the word "random" in the claimed context, and that this was consistent with other district court decisions, including denial of Defendants' motion in limine on this issue.

    The panel also affirmed as being supported by substantial evidence the jury's infringement decision, and consequently, that the District Court did not err in denying Defendants' motion for JMOL.  The opinion provided a synopsis of the parties' evidence, including differing expert witnesses on infringement, supported by Baxalta's submissions to FDA regarding the specificity with which its Factor VIII product comprised "controlled, targeted chemical addition of 20 [kilodalton] PEG conjugates to this FVIII B-domain" (emphasis in opinion), statements inconsistent with random PEGylation.

    Similarly, the Federal Circuit held that there was substantial evidence for the jury's rejection of Defendants' non-enablement defense, particularly with regard to embodiments comprising non-random lysine PEGylation.  According to the opinion, "Bayer presented substantial evidence from which a reasonable juror could find that the specification's disclosure of instructions as to the reaction conditions required to practice the claimed invention using cysteine PEGylation were sufficient to enable not only non-random cysteine PEGylation at the B-domain, but also non-random lysine PEGylation at the B-domain."  Somewhat in contrast to recent, more stringent applications of the Federal Circuit's standards for enablement (see Amgen Inc. v. Sanofi and Idenix Pharmaceuticals LLC v. Gilead Sciences Inc.), this panel held that "the specification need not include a working example of every possible embodiment to enable the full scope of the claims," citing Alcon Rsch. Ltd. v. Barr Labs., Inc., 745 F.3d 1180, 1189–90 (Fed. Cir. 2014), and Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1336–37 (Fed. Cir. 2003).

    Defendants also appealed the jury's damages calculations and the basis thereof.  While agreeing with the District Court in rejecting Bayer's expert's 50-50 split royalty rate, the panel disagreed with several other assertions of error by Defendants.  These included the basis for the 17.78% reasonable royalty rate, which Defendants' argued relied on a "a flawed and speculative methodology—namely, asking the jury to pick a rate between the range of feasible rates presented by [Bayer's expert] as the reasonable rate."  The Federal Circuit held that "[t]he district court properly exercised its discretion in allowing Bayer to ask the jury to select a rate between the range presented," within the confines of a damages expert using "reliable methodology for determining the range of possible hypothetical negotiation royalty rates."  When, as here, a jury's damages award "fell within the range suggested by the patentee's damages expert" the Federal Circuit stated it was supported by substantial evidence, citing Rembrandt Wireless Techs., LP v. Samsung Elecs. Co., 853 F.3d 1370, 1382 (Fed. Cir. 2017), and that the District Court had not erred in permitting the jury to received Bayer's damage expert's testimony.  Defendants had had (and had exercised) the opportunity to cross-examine Bayer's expert on his methodology and damaged calculation, according to the opinion, and "ultimately, the jury evaluated his opinions and adopted a rate within his proposed range."  In the Federal Circuit's opinion there was nothing improper about the jury's damages calculation or award.

    Finally, Defendants argued that the District Court had violated their Seventh Amendment rights by awarding pre-judgment damages under Fed R Civ Pro 59.  In doing so, according to the Federal Circuit, the District Court used actual sales data instead of projected amounts and applied the same 17.78% royalty rate on the amount of these actual sales.  "Under these circumstances," said the Federal Circuit, "we are not persuaded that the District Court's award constitutes an impermissible additur or an otherwise 'bald addition of something which in no sense can be said to be included in the verdict,'" citing Dimick v. Schiedt, 293 U.S. 474, 486 (1935) (the remainder of the Court's opinion making it clear that its judgment was limited to the facts in this case).

    Regarding Bayer's appeal on the District Court's grant of Defendants' motion for JMOL on willful infringement, the panel held that there was insufficient evidence of the necessary "state of mind" having "a specific intent to infringe at the time of the challenged conduct" to support willfulness, citing Halo Elecs., Inc. v. Pulse Elecs., Inc., 136 S. Ct. 1923, 1933 (2016) ("willful, wanton, malicious, bad-faith, deliberate, consciously wrongful, flagrant, or—indeed—characteristic of a pirate").  The panel affirmed the District Court's decision even though "there was no dispute that Baxalta was 'aware of the '520 patent,'" because "Bayer merely 'assume[d] that [Baxalta] knew Adynovate[®] infringed because it involved pegylation at the B-domain of factor VIII."  The Federal Circuit rendered this opinion even in the face of testimony by Defendants' witnesses "concerning their awareness of the patent application that issued as the '520 patent" and representations to FDA regarding non-random PEGylation in Defendants' Adynovate® product.

    Bayer Healthcare LLC v. Baxalta Inc. (Fed. Cir. 2021)
    Panel: Circuit Judges Newman, Linn, and Stoll
    Opinion by Circuit Judge Stoll

  • By Donald Zuhn —

    Tillis  ThomLast month, Sen. Thom Tillis (R-NC), the Ranking Member of the Subcommittee on Intellectual Property of the Senate Committee on the Judiciary, sent a letter to President Biden regarding the selection of the next Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office.  Sen. Tillis (at right) noted that "at this critical juncture in our nation's history, we cannot take our innovation and creative economy for granted," and urged the President to work together with Congress "to provide strong protections for our innovative and creative works."  With respect to the next USPTO Director, Sen. Tillis outlined five characteristics that he believed any nominee "must possess":

    • The nominee "must truly appreciate and value American intellectual property and must treat it for what it is — a vested property right," and "should understand that clear, predictable, and enforceable intellectual property protections are absolutely critical, and must commit to do everything in their power to strengthen and protect those rights."

    • The nominee must commit to continuing the administrative reforms made by the previous Director, Andrei Iancu.  Pointing in particular to Director Iancu's reforms to the Patent Trial and Appeals Board (PTAB), Sen. Tillis noted that the prior Director's reforms "have ensured that all rights holders, from individual inventors to innovative startups to industry titans, receive fair and equitable treatment."  Sen. Tillis indicated that the next Director must ensure that the USPTO "doesn't return to being viewed as a 'death squad' for intellectual property rights."

    • The nominee "must understand the importance of critical and emerging technologies to America's innovation economy and national security," noting that such technologies include precision medicine, quantum computing, artificial intelligence, 5G, and the internet of things, which Sen. Tillis indicated "will be critical to maintaining America's global dominance, both from economic and security perspectives."  According to Sen. Tillis, the next Director should ensure that "private actors have the incentive to invest in the research and development" of such technologies.

    • The nominee "must be a consistent advocate for the inclusion of strong intellectual property protections in all of our future trade agreements."  In particular, Sen. Tillis believes the next Director "should be an advocate and thought leader for new, modern, and ultimately stronger intellectual property protection standards in all international agreements."

    • The nominee "must be committed to increasing diversity in our nation's intellectual property system."  Sen. Tillis declared that "[f]or too long, too many women and people of color have been underrepresented in our innovation ecosystem," stating that "[t]hese individuals often face unique barriers to engaging in the intellectual property system and their lack of access costs our economy billions of dollars every year."  Sen. Tillis believes the next Director should be "committed to increasing the voluntary participation of underrepresented groups in our innovation ecosystem."

    Sen. Tillis concluded his letter by noting that "given the importance of strong intellectual property protections to our nation's innovation and creative economy, our trade relationships, and our national security, it is vital that whomever you select for this critical position meets all of these qualifications and truly appreciates and values intellectual property as a right."  And the Senator indicated that "[a]nyone who fails to meet these standards will not receive my vote."

  • CalendarMarch 9, 2021 – Summit on Women Leaders in IP Law (American Conference Institute) – 8:45 am to 5:15 pm EST

    March 9, 2021 – "Herstory of Invention" (Intellectual Property Owners Association (IPO) Education Foundation) – 5:00 pm to 6:00 pm (ET)

    March 10, 2021 – "Pathways to invention, entrepreneurship, and STEM careers for students K-12 and beyond" (U.S. Patent and Trademark Office) – 12:00 pm to 1:30 pm (ET)

    March 10, 2021 – "Using Persuasion Techniques to Achieve Litigation Success: Part One" (Fitch Even) – 12:00 pm to 1:00 pm (ET)

    March 11, 2021 – "What Happens When It Goes Wrong? Avoiding Loss of Patent Rights in Portfolio Management" (HGF Limited) – 6:00 am (ET)

    March 24-25, 2021 – FDA Boot Camp (American Conference Institute)

    April 26-27, 2021 – Paragraph IV Disputes Conference (American Conference Institute)

  • IPO #2The Intellectual Property Owners Association (IPO) Education Foundation will offer a webinar in the Behind the IDEA series, entitled "Herstory of Invention," on March 9, 2021 from 5:00 pm to 6:00 pm (ET).  Sandra Nowak of 3M Innovative Properties Co. will moderate a panel consisting of Marian Croak of Google, Sumita Mitra of Mitra Chemical Consulting, and Lisa Seacat Deluca of IBM Corp., three inventors who have more than 800 patents among them.  The panelists will discuss their journeys, obstacles they faced in their careers, and their views on the importance of diversity in innovation.

    There is no registration fee for the webinar.  However, those interested in attending the webinar should register here.

  • USPTO SealThe U.S. Patent and Trademark Office will be holding the next installment of the 2021 Women's Entrepreneurship Symposium, entitled "Pathways to invention, entrepreneurship, and STEM careers for students K-12 and beyond," on March 10, 2021, from 12:00 pm to 1:30 pm (ET).  The Symposium, which is being held as a free online event, will allow attendees to:

    • Opportunities for girls and women in computer science, invention, and STEM
    • Nurturing girls' confidence in entrepreneurship
    • Philanthropy and programs to encourage young women in invention and STEM

    Joyce Ward, Director, Office of Education, U.S. Patent and Trademark Office will moderate a panel consisting of Carol Dahl of The Lemelson Foundation; Rozalynn Goodwin, Co-founder of Confidence; and Ruthe Farmer of CSforAll.

    Additional information regarding the Symposium, including an agenda and list of speakers, can be found here.  Those interested in registering for the event, can do so here.

  • HGFHGF Limited will be offering a webinar entitled "What Happens When It Goes Wrong?  Avoiding Loss of Patent Rights in Portfolio Management" on March 11, 2021 at 6:00 am (ET).  Vanessa Stainthorpe of HGF Limited will use case studies to help recognise risky practices in portfolio management and outline what can be done when something goes wrong, explain the circumstances in which patent applications can (and can't) be restored, for example using the European Patent Office's further processing and reinstatement procedures, discuss recent case law decisions, and give practical advice on how to avoid losing valuable patent rights.

    Those wishing to register can do so here.

  • Fitch EvenFitch Even will be offering a webinar entitled "Using Persuasion Techniques to Achieve Litigation Success: Part One" on March 10, 2021 from 12:00 pm to 1:00 pm (ET).  Karl R. Fink, Nikki Little, and Timothy P. Maloney of Fitch Even will discuss the following topics:

    • An introduction to the concepts of ethos, pathos, and logos
    • How to integrate persuasion techniques when developing case themes
    • The importance of building a team that can communicate and persuade
    • How to select and prepare effective fact witnesses

    While there is no cost to participate in the program, advance registration is required.  Those interested in attending the webinar can register here.

  • ACIAmerican Conference Institute (ACI) will be holding its 15th Annual Paragraph IV Disputes Conference on April 26, 2021 from 8:00 am until 5:30 pm (EST) and April 27, 2021 from 9:00 am until 5:00 pm (EST) as a VIRTUAL conference.

    The conference opens with a Regional Breakfast Meeting directed to a "China Strategy Session: An Inside Look at the Reformations to the Patent Law of the People's Republic of China Relative for the Hatch-Waxman Practitioner." ACI faculty will give presentations on:

    • Patents, Prices, and Politics: Unwritten Lessons from the Election and Geopolitical Developments (virtual town hall format)
    •
    GSK v. Teva: What's the Skinny on Carve Outs?
    • Spotlight on Delaware: Fireside Chat with Chief Judge Stark and Judge Noreika
    • Diversity, Inclusion, Incorporation: How to Manage and Maintain a Diverse Pharmaceutical IP Team
    • You Can't Go Home Again . . . or Can You Establishing Venue in PIV Litigation Post Valeant v. Mylan
    • Pharmaceutical Patent Litigation in the EU: A New Look at Bolar Exemptions and Recent Critical Developments Impacting Pharmaceutical Litigation
    • Challenges and Opportunities in an Evolving Landscape Featuring USPTO, FDA, and FTC
    • Definitely, Maybe: Determining Patentable Subject Matter and the Future of Section 101
    • A View from the Bench: District Court Judges Address Brand and Generic Concerns, featuring the Hon. Alan D. Albright, USDC, TX Western District
    • A Study in Stats, Status, Standing, and Sustainability: The PTAB Year in Review, featuring the Hon. Jacqueline Wright Bonilla, Vice Chief Administrative Judge, PTAB
    • Debating the Applicability of the Doctrine of Assignor Estoppel: What Every Hatch-Waxman Practitioner Needs to Know about the Anticipated SCOTUS Decision in Hologic v. Minerva
    •
    The Ethical Practice of Paragraph IV Litigation: New Developments Impacting Professional Responsibility in the Hatch-Waxman Arena

    There will also be back-to-back break-out sessions, with the alternatives being "The Economics and Economy of Drug Patents with ACI's Hatch-Waxman Series Advisory Board Members Optimizing Product Selection, Identifying Targets for Litigation and Monetizing IP Portfolios" or "The Practice of Hatch-Waxman Litigation: PIV on Trial Structuring Settlements and Antitrust Considerations for the PIV Litigator."  The first day will also feature faculty-attendee roundtables at the end of the day.

    An agenda for the conference and additional information regarding the workshops can be found here.  A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.

    The registration fee for the conference alone is $1,595 (paid registration by March 11th) or $1,695 for paid registration by April 25, 2021.  ACI is offering a discount rate for in-house counsel for $1,295.  Patent Docs readers are entitled to a 10% discount off of registration using discount code D10-896-896DX01.  Those interested in registering for the conference can do so here, by e-mailing CustomerService@AmericanConference.com, or by calling 1-888-224-2480.

    Patent Docs is a media partner of ACI's 15th Annual Paragraph IV Disputes.

  • By Kevin E. Noonan —

    On March 1st, the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) issued its Order on the Preliminary Motions Lists submitted by Junior Party University of California/Berkeley, University of Vienna, and Emmanuelle Charpentier (collectively, "CVC") and Senior Party ToolGen Inc. in Interference No. 106,127.  (Somewhat curiously, the Board did not issue an Order in Interference No. 106,126 between The Broad Institute, Harvard University, and the Massachusetts Institute of Technology (collectively, "Broad") and Senior Party Toolgen on similar interfering subject matter.)

    CVC had requested permission to file six proposed motions (one of which is Motion No. 6 under 37 C.F.R. § 41.208(a)(4), which seeks judgment based on priority, which was routinely deferred to the Priority Phase of the interference).  CVC Motion No. 1 under 37 C.F.R. §§ 41.121(a)(1)(ii) and 41.208(a)(3) seeks to be awarded priority to their first-filed priority applications (specifically, in the alternative either the P1 or P2 applications), as set forth in this diagram:

    2021-03-04 ImageThe Board GRANTED this motion, because "no estoppel yet applies to the decision on CVC benefit made in Interference 106,115 (where the Board granted CVC the benefit of priority no earlier than U.S. Patent Application No. 61/757,640).

    The Board also GRANTED CVC's Motion No. 2 seeking to have the Board deny the benefit of ToolGen's priority application, U.S. Provisional Application No. 61/717,324, filed October 12, 2012.

    The Board further GRANTED CVC's Motion No. 3 to include ToolGen's U.S. Patent No. 10,851,380 on the grounds that these claims correspond to the Count; specifically "methods of introducing a site-specific, double-stranded break at a target nucleic acid sequence in a eukaryotic cell, the method comprising introducing a chimeric guide RNA (i.e., a single guide RNA) and Cas9 into the eukaryotic cell."

    The Board DEFERRED to the Priority Phase of the interference CVC's motions that ToolGen's involved claims were unpatentable.  The first of these, CVC's Motion No. 4, is for judgment that ToolGen's claims are unpatentable over CVC's U.S. Patent Application Publication No. 2014/0068797, which claims the benefit of priority to the P1 provisional application illustrated above.  The second, CVC's Motion No. 5, is for judgment that ToolGen's claims are unpatentable under 35 U.S.C. §§ 102 or 103 over U.S. Patent Application Publication No. 2016/0298138.  The Board's basis for deferring these motions is that "determination of patentability issues that do not impact the determination of priority during an interference is discretionary" under 35 U.S.C. § 135(a), and is not (nor has ever been) a threshold issue.  The Board's Order notes in this regard that a holding during the course of interference that a party's claims are unpatentable over prior art does not necessarily deprive that party of standing on the central issue of an interference — priority, citing 37 C.F.R. § 41.201.

    Should CVC prevail on Motions No. 1 or 2 they would become the Senior Party to this interference.

    ToolGen's Motions List contained eight motions including its Motion for Judgment on priority basis.  The Board DENIED ToolGen's Expedited Miscellaneous Motion No. 1 under 37 C.F.R. §1.645(d) that this interference should be stayed pending Final Judgment in Interference No. 106,115, because this motion is not one "to changing the status quo of the interference as declared in preparation for a priority phase, if one is necessary."

    The Board GRANTED ToolGen's Motion No. 2 (hereinafter designated TOOLGEN MOTION 1) under 37 C.F.R. §§ 41.121(a)(1)(ii) and 41.208(a)(3) that seeks to be granted the priority benefit of U.S. Provisional Application Publication No. 61/837,481, filed June 20, 2013; and PCT Application KR2013/009488, filed October 23, 2013.

    The Board also GRANTED ToolGen's Motion No. 3 (hereinafter designated TOOLGEN MOTION 2) under 37 C.F.R. §§ 41.121(a)(1)(ii) and 41.208(a)(3) attacking the priority benefit granted to CVC on the basis of U.S. Provisional Application No. 61/757,640, filed on January 28, 2013.

    The Board DENIED ToolGen's request to file Motion No. 4 under 37 C.F.R. § 41.121(a)(1)(iii) for judgment that the involved patents or applications of each Junior Party are unpatentable for failure to satisfy the written description and enablement requirements of 35 U.S.C. § 112(a).  The Board's basis for denying the request is that "ToolGen did not allege that CVC's application claims were first made after the publication of ToolGen's application."

    ToolGen's Motion No. 5 under 37 C.F.R. § 41.121(a)(1)(iii) for judgment that the involved patents or applications are unpatentable under 35 U.S.C. § 102 or § 103 was DEFERRED by the Board until the priority phase, on similar grounds upon which the Board based its denial of CVC's similar requests.

    The Board ORDERED ToolGen, pursuant to its Motion No. 6 for a protective order under 37 C.F.R. § 42.54, to submit a proposed protective order to keep Toolgen's Priority Statement sealed until the priority phase of the interference commences (the request to file Motion No. 6 was dismissed as moot accordingly).  The Board's reasoning set forth in the Order was that "[d]uring Interference 106,115, CVC argued to have its priority statement filed under seal because, in part, competitors, including ToolGen and Sigma-Aldrich were pursuing patent applications claiming subject matter that might interfere with CVC's claims involved in that interference."  (Indeed, this interference validates CVC's previous apprehension in this regard.)  Based on the Board's earlier decision in the '115 Interference, this panel believes Toolgen's similar apprehension here has merit.

    Finally, the Board DENIED ToolGen's Miscellaneous Motion No. 7 under 37 C.F.R. § 41.104(a) for the Board to order the '126 and '127 Interferences to proceed on the same schedule.  The Board's reasoning is that "ToolGen is free to agree or disagree with proposed changes in the schedule [set forth in the Order] and the Board expects all parties to cooperate on scheduling issues."

    The Board refused to waive the requirement 37 C.F.R. § 41.121(d) for statements of material facts in each motion (which count against the page limits for each) but waived the requirement for consecutive exhibit number under Standing Order ¶ 154.2.1.

    The Board set out the following briefing schedule, subject to agreement by the parties to change the schedule for TIME PERIODS 1-6:

    TIME PERIOD 1 ……………………………………………………. 9 April 2021
    File motions
    File (but serve one business day later) priority statements

    TIME PERIOD 2 ……………………………………………………. 14 May 2021
    File responsive motions to motions filed in TIME PERIOD 1

    TIME PERIOD 3 …………………………………………………… 25 June 2021
    File oppositions to all motions

    TIME PERIOD 4 ……………………………………………………6 August 2021
    File all replies

    TIME PERIOD 5 ………………………………………………17 September 2021
    File request for oral argument
    File motions to exclude
    File observations

    TIME PERIOD 6 …………………………………………………..8 October 2021
    File oppositions to motions to exclude
    File response to observations

    TIME PERIOD 7 ………………………………………………….15 October 2021
    File replies to oppositions to motions to exclude

    DEFAULT ORAL ARGUMENT DATE ………………………………………….. TBD

  • By James Lovsin —

    Supreme Court Building #3As discussed here, the Justices asked many questions in the oral argument in Arthrex this week on both questions:  (1) whether there was an Appointments Clause defect and (2) if so, whether the Federal Circuit properly cured it.  With respect to the first question, several of the Justices appeared skeptical that administrative patent judges are "inferior officers" as argued by the government and Smith & Nephew.  Instead, the Court may well affirm the Federal Circuit's holding that the appointment of administrative patent judges to the Patent Trial and Appeal Board violated the Appointments Clause.

    What was much less clear from the argument, however, was the Justice's views on the second question.  While the Federal Circuit's cure (prospectively severing a portion of the AIA restricting the way APJs can be removed) did not get much attention during the argument, no other approach appeared to have a consensus either.

    Interestingly, the issue of historical practice of the USPTO came up during oral argument.  Justice Kagan asked Smith & Nephew's attorney, Mr. Perry, the story behind the scope of administrative patent judge's authority.  Mr. Perry noted interference examiners going back to 1836, which decided interference proceedings and were appointed by the Secretary of Commerce, as part of "the long and proud history of the Patent Office."  Mr. Perry continued:  "[w]e have a patent-specific tradition [that] comes out of the examination process" and "modern APJs are very much in line with a long, long history that, in fact, stretches all the way back to the founding."

    Justice Gorsuch followed up and asked Mr. Perry to admit that administrative patent judges are "a rare bird" and "this is an unusual animal in the sense that there isn't final review in the agency head."  Mr. Perry acknowledged "[i]t is unusual, but it is also well and historically founded and . . . until now, unchallenged."

    Smith & Nephew's reliance on historical practice appears misplaced.  Over twenty years ago, the Supreme Court rejected history and tradition in Dickinson v. Zurko, 527 U.S. 150 (1999).  There, the Supreme Court held that the Administrative Procedure Act's (APA) substantial evidence review for agency fact finding applied to appellate review of the USPTO's fact finding.  In doing so, the Court disagreed with the Federal Circuit's position that clear error review of USPTO fact finding applied because that was the standard of review used by the Court of Customs and Patent Appeals before the APA was enacted in 1946.  Chief Justice Rehnquist, joined by Justices Kennedy and Ginsburg, dissented and would have deferred to "the unanimous en banc Federal Circuit and the patent bar."

    Just as Smith & Nephew noted that the appointment of administrative patent judges was "until now unchallenged," so too was the clear error standard of review for USPTO fact finding for over 50 years before Zurko.  The USPTO argued in Zurko that the APA trumped historical practice.

    For similar reasons, Smith & Nephew's reliance on a "patent-specific tradition" appears misplaced.  Since at least eBay Inc. v. Mercexchange LLC, 547 U.S. 388 (2006), the Supreme Court has sought to avoid patent law diverging from other areas of the law.

    If the Supreme Court rules administrative patent judges are inferior officers, it will be surprising to see the Court rely on the history of interference examiners and patent-specific tradition.